Sana Alajmovic is the co-founder and current CEO of Sigrid Therapeutics. She brings extensive experience from business development and leadership within the life science sector, with a strong track record in commercializing research and developing strategic partnerships with international pharmaceutical and consumer health companies. Known for her strategic thinking and dynamic, empathetic leadership, she has established herself as a pioneer in the industry.

"Sana Alajmovic is the perfect match for Enzymatica. Her background in life sciences, strong drive, and proven commercial acumen makes her well suited to lead the company in the next phase. She combines strategic vision with a clear focus on results and has a rare ability to build partnerships and drive growth. We are very pleased to welcome her as our new CEO", says Bengt Baron, Chairman of the Board, Enzymatica AB.

Sana Alajmovic has received several awards for her entrepreneurship and leadership, including Sweden's Most Important Female Founder by Dagens Industri in 2021 and Female Leader of the Future by Ledarna in both 2020 and 2021. She has also been named one of the world's top life science innovators under the age of 40.

"As the new CEO of Enzymatica, my focus is to lead the company into its next phase of growth. In a global market worth over SEK 300 billion, where competitors rely on outdated and generic products without clinically proven efficacy, I see great opportunities for Enzymatica to take a leading position with a unique, evidence-based alternative.
ColdZyme is a consumer favorite with a repurchase rate of over 90 percent. The product is used at the first sign of a cold and breaks the viral cycle at the onset of symptoms. Clinical studies show that ColdZyme reduces viral load by 94 percent - helping to cut illness duration in half, ease symptoms, and speed up recovery. To me, it's clear - ColdZyme represents the future of cold relief." says Sana Alajmovic.

Sana Alajmovic will assume her new role no later than 31 January 2026.